A Novel Two‐Part Mixture Model for the Incidence and Time Course of Cytokine Release Syndrome After Elranatamab Dosing in Multiple Myeloma Patients

多发性骨髓瘤 医学 入射(几何) 人口 启动(农业) 免疫学 生物 数学 几何学 植物 环境卫生 发芽
作者
Donald Irby,Jennifer Hibma,Mohamed Elmeliegy,Diane Wang,Erik Vandendries,Kamrine E. Poels,Blerta Shtylla,Jason H. Williams
出处
期刊:Clinical Pharmacology & Therapeutics [Wiley]
被引量:1
标识
DOI:10.1002/cpt.3533
摘要

Cytokine release syndrome (CRS) is a common, acute adverse event associated with T‐cell redirecting therapies such as bispecific antibodies (BsAbs). The nature of CRS events data makes it challenging to capture an unbiased exposure–response relationship with commonly used models. For example, simple logistic regression models cannot handle traditional time‐varying exposure, and static exposure metrics chosen at early time points and with lower priming doses may underestimate the incidence of CRS. Therefore, more advanced modeling techniques are needed to adequately describe the time course of BsAb‐induced CRS. Herein, we present a two‐part mixture model that describes the population incidence and time course of CRS following various dose‐priming regimens of elranatamab, a humanized BsAb that targets the B‐cell maturation antigen on myeloma cells and CD3 on T cells, where the conditional time‐evolution of CRS was described with a two‐state (i.e., CRS‐yes or no) Markov model. In the first part, increasing elranatamab exposure (maximum elranatamab concentration at first CRS event time ( C max,event )) was associated with an increased CRS incidence probability. Similarly, in the second part, increased early elranatamab exposure ( C max,D1 ) increased the predicted probability of CRS over time, whereas premedication including corticosteroids and IL‐6 pathway inhibitors use demonstrated the opposite effect. This is the first reported application of a Markov model to describe the probability of CRS following BsAb therapy, and it successfully explained differences between different dose‐priming regimens via clinically relevant covariates. This approach may be useful for the future clinical development of BsAbs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
冰凌心恋完成签到,获得积分10
刚刚
3秒前
magicfu完成签到,获得积分10
4秒前
科研通AI2S应助善良的白昼采纳,获得10
4秒前
4秒前
计时器响了完成签到,获得积分10
7秒前
7秒前
skycrygg完成签到,获得积分10
8秒前
完美世界应助科研通管家采纳,获得10
9秒前
NexusExplorer应助科研通管家采纳,获得10
9秒前
田様应助科研通管家采纳,获得10
9秒前
herococa应助科研通管家采纳,获得40
9秒前
fhr完成签到,获得积分10
10秒前
magicfu发布了新的文献求助10
11秒前
百里伟祺发布了新的文献求助10
19秒前
xzy998应助善良的白昼采纳,获得10
20秒前
sheila完成签到,获得积分10
20秒前
周晏平发布了新的文献求助10
22秒前
skycrygg521完成签到,获得积分10
22秒前
23秒前
ren关闭了ren文献求助
25秒前
打打应助fhr采纳,获得10
26秒前
26秒前
27秒前
lelehanhan完成签到,获得积分20
28秒前
28秒前
30秒前
百里伟祺完成签到,获得积分10
30秒前
灵巧觅山发布了新的文献求助10
31秒前
冰火完成签到,获得积分10
31秒前
112完成签到,获得积分10
32秒前
32秒前
mirrovo发布了新的文献求助30
33秒前
peacat发布了新的文献求助10
34秒前
lelehanhan发布了新的文献求助10
35秒前
JamesPei应助周晏平采纳,获得10
36秒前
36秒前
37秒前
莫x莫完成签到 ,获得积分10
38秒前
39秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
Периодизация спортивной тренировки. Общая теория и её практическое применение 310
Mixing the elements of mass customisation 300
the MD Anderson Surgical Oncology Manual, Seventh Edition 300
Nucleophilic substitution in azasydnone-modified dinitroanisoles 300
Platinum-group elements : mineralogy, geology, recovery 260
Geopora asiatica sp. nov. from Pakistan 230
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3780426
求助须知:如何正确求助?哪些是违规求助? 3325838
关于积分的说明 10224370
捐赠科研通 3040879
什么是DOI,文献DOI怎么找? 1669111
邀请新用户注册赠送积分活动 799013
科研通“疑难数据库(出版商)”最低求助积分说明 758649